How do you decide between radioligand therapy or cytotoxic chemotherapy in patients with metastatic castrate resistant prostate cancer with prior ARPI exposure who have anemia related to the cancer?

Given that both carry risks of worsening anemia, and both potentially may help the anemia if disease related, how do you come up with your decision? How do you provide supportive care throughout the process?

Please select the option that best describes you:

How do you decide between radioligand therapy or cytotoxic chemotherapy in patients with metastatic castrate resistant prostate cancer with prior ARPI exposure who have anemia related to the cancer?

Related Questions